Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Ticker SymbolCELZ
Company nameCreative Medical Technology Holdings Inc
IPO dateMay 01, 2009
CEOMr. Timothy Warbington
Number of employees4
Security typeOrdinary Share
Fiscal year-endMay 01
Address211 E. Osborn Rd.
CityPHOENIX
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code85012
Phone14803992822
Websitehttps://creativemedicaltechnology.com/
Ticker SymbolCELZ
IPO dateMay 01, 2009
CEOMr. Timothy Warbington
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data